Acorda Therapeutics

Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders.

We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders.

We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by:

• investing in research and development

• collaborating closely with the patient, medical and scientific communities

• retaining employees with compassion and commitment

Acorda has been voted one of the best companies to work for in New York for the past five years in a row, as a result of our dynamic environment, strong corporate culture, significant emphasis on research and development, and a robust product pipeline. We are positioned to be an industry leader, poised for exceptional growth.

Type
Public
HQ
Ardsley, US
Founded
1995
Size (employees)
597 (est)+12%
Website
acorda.com
Acorda Therapeutics was founded in 1995 and is headquartered in Ardsley, US

Acorda Therapeutics Office Locations

Acorda Therapeutics has offices in Ardsley, Chelsea
Ardsley, US (HQ)
420 Saw Mill River Rd
Chelsea, US
190 Everett Ave

Acorda Therapeutics Metrics

Acorda Therapeutics Financial Metrics

Revenue (2016)

$519.6 m

Revenue growth (2015-16), %

5%

Gross profit

$412.1 m

Gross profit margin (2016), %

79%

Net income (2016)

($35.6 m)

Market capitalization (17-Mar-2017)

$1.2 b

Closing share price (17-Mar-2017)

$27.7

Cash (31-Dec-2016)

$158.5 m
Acorda Therapeutics's current market capitalization is $1.2 b.
Acorda Therapeutics's revenue was reported to be $519.6 m in FY, 2016 which is a 5.5% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$336.4 m$401.5 m$492.7 m$519.6 m

Revenue growth, %

19%23%5%

Cost of goods sold

$66 m$80 m$92.3 m$107.5 m

Gross profit

$270.4 m$321.5 m$400.4 m$412.1 m

Gross profit Margin, %

80%80%81%79%

R&D expense

$53.9 m$73.5 m$149.2 m$203.4 m

General and administrative expense

$185.5 m$201.8 m$205.6 m$235.4 m

Operating expense total

$306.1 m$365.1 m$458.7 m$555.6 m

EBIT

$30.4 m$36.4 m$34 m($36 m)

EBIT margin, %

9%9%7%(7%)

Interest expense

($2.2 m)($9.3 m)($15.5 m)($16.5 m)

Interest income

$668 k$674 k$440 k$339 k

Pre tax profit

$28.9 m$28 m$19.4 m($42.3 m)

Income tax expense

($8.3 m)$6.7 m

Net Income

$16.4 m$17.7 m$11.1 m($35.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$48 m$182.2 m$153.2 m$158.5 m

Accounts Receivable

$1 m

Current Assets

$367.3 m$409.1 m$451.3 m$272.7 m

PP&E

$16.5 m$46.1 m$40.2 m$34.3 m

Goodwill

$183 m$183.6 m$280.6 m

Total Assets

$607.1 m$1.1 b$1.1 b$1.3 b

Accounts Payable

$4.2 m$6.2 m$1.9 m

Total Debt

$331.1 m

Current Liabilities

$96.6 m$114.4 m$90.6 m$147.9 m

Common Stock

$46 k

Additional Paid-in Capital

$678.7 m$761 m$812.8 m$921.4 m

Retained Earnings

($238.1 m)($220.4 m)($209.4 m)($244 m)

Total Equity

$440.4 m$540.3 m$603 m$664.2 m

Debt to Equity Ratio

0.5 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.4 x2 x1.9 x2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$16.4 m$17.7 m$11.1 m($35.6 m)

Depreciation and Amortization

$7 m$8.5 m$15 m$21.6 m

Accounts Payable

$59.9 k$59.9 k($90.5 k)

Cash From Operating Activities

$6.2 m$134.1 m($29 m)$35.3 m

Purchases of PP&E

($4 m)($5.1 m)($5.9 m)($6.2 m)

Cash From Investing Activities

($45.1 m)($293.8 m)($85.2 m)($73.8 m)

Cash From Financing Activities

$12 m$352.9 m$17.8 m$45.9 m

Interest Paid

$2 m$4.5 m$7.2 m$6.1 m

Income Taxes Paid

$2.6 m$4.4 m$4.7 m$4.3 m

Acorda Therapeutics Market Value History

Acorda Therapeutics Job Categories

Acorda Therapeutics Online Presence

Acorda Therapeutics Company Life

You may also be interested in